ES0167733015
© Globe Newswire
15.12.2025
ORY
LISTED
BME
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
News Preview
MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
ORY
LISTED
BME
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
News Preview
MADRID and CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today reported financial results for the nine months ended September 30, 2025 and provided a corporate update on recent developments....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ORY
LISTED
BME
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
News Preview
MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics, today announced that the first patient has been enrolled in RESTORE, its multi‑center, open‑label Phase Ib clinical trial of iadademstat in adults...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
30.10.2025
ORY
LISTED
BME
ORYZON to Participate in Upcoming Events in November
News Preview
MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events:...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
17.10.2025
ORY
LISTED
BME
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
News Preview
MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the Phase III protocol to eva...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
ORY
LISTED
BME
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
News Preview
MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent application EP20712594.9, entitled “Combinations of...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
ORY
LISTED
BME
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
News Preview
In Australia and Europe In Australia and Europe...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ORY
LISTED
BME
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
News Preview
MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA), the European equivalent to an IND,...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
ORY
LISTED
BME
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025
News Preview
MADRID and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today reported financial results for the half-year ended June 30, 2025 and provided a corporate update on recent developments....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.07.2025
ORY
LISTED
BME
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
News Preview
MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office fo...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2025
ORY
LISTED
BME
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29
News Preview
MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its Chief Scientific Officer, Dr. Jordi Xaus will be attending the 2025 Phelan-McDermid Syndrome Congress in Barcelona on June 26...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
ORY
LISTED
BME
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025
News Preview
MADRID and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update on recent developments....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
08.05.2025
ORY
LISTED
BME
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
News Preview
MADRID and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the publication of the Spanish provisional resolution proposal for Med4Cure, the first Important Project of Common European Interest (I...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.04.2025
ORY
LISTED
BME
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
News Preview
New “Decision to grant” communications in Europe and Japan New “Decision to grant” communications in Europe and Japan...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.03.2025
ORY
LISTED
BME
ORYZON to Provide Corporate Progress Updates at Several Events in March-April
News Preview
MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several int...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
ORY
LISTED
BME
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat
News Preview
MADRID and CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the final results of an observational clinical study aimed at psychometrically...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.02.2025
ORY
LISTED
BME
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting
News Preview
MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced the results of voting at the Extraordinary General Shareholders' Meeting held today in Mad...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.02.2025
ORY
LISTED
BME
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences
News Preview
MADRID and CAMBRIDGE, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the final results of the Phase IIa REIMAGINE study, which evaluated the safety...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2025
ORY
LISTED
BME
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting
News Preview
MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board of Directors at the upcoming Shareholders' Meeting, sched...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
ORY
LISTED
BME
ORYZON to Provide Corporate Progress Updates at Several Events in January-February
News Preview
MADRID and CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several internation...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2024
ORY
LISTED
BME
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024
News Preview
MADRID and CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the nine months ending September 30, 2024 and provided a corpor...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2024
ORY
LISTED
BME
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
News Preview
MADRID and CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the receipt of the official meeting minutes from a recent End-of-Phase II meeting fo...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
ORY
LISTED
BME
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress
News Preview
MADRID and CAMBRIDGE, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that it will present today the final data from its Phase IIb PORTICO trial of vafidemstat...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2024
ORY
LISTED
BME
ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
News Preview
From the European Patent Office From the European Patent Office...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2024
ORY
LISTED
BME
ORYZON to Provide Corporate Progress Updates at Several Events in September
News Preview
MADRID, Spain and CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several inte...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2024
ORY
LISTED
BME
ORYZON reports financial results and corporate update for half-year ending June 30, 2024
News Preview
MADRID and CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the half-year ending June 30, 2024 and provided a corporate upd...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
ORY
LISTED
BME
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
News Preview
MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced the voting results from its Annual General Meeting of Shareholders held today in Madrid....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.06.2024
ORY
LISTED
BME
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
News Preview
MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents preliminary data from its ongoing Phase Ib FRIDA study investigating iadademstat in c...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
ORY
LISTED
BME
ORYZON to Provide Corporate Progress Updates at Several Events in May
News Preview
MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several inter...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2024
ORY
LISTED
BME
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024
News Preview
MADRID, Spain and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the quarter ended March 31, 2024 and provided a corpora...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
